Daphne Koller, Noubar Afeyan, and Dr. Eric Topol, leaders in AI-driven medicine, discuss how AI is changing biomedical research and discovery, from accelerating drug target identification and biotech R&D to helping pursue the “holy grail” of a virtual cell.

Show notes

Professors Daniel Carpenter and Timo Minssen explore evolving pharma and medical device regulation, including the role of clinical trials, while Microsoft applied scientist Chad Atalla shares where AI governance stakeholders might find inspiration in the fields.

Show notes

In this episode, Alta Charo, emerita professor of law and bioethics at the University of Wisconsin–Madison, joins Sullivan for a conversation on the evolving landscape of genome editing and its regulatory implications. Drawing on decades of experience in biotechnology policy, Charo emphasizes the importance of distinguishing between hazards and risks and describes the field's approach to regulating applications of technology rather than the technology itself. The discussion also explores opportunities and challenges in biotech’s multi-agency oversight model and the role of international coordination. Later, Daniel Kluttz, a partner general manager in Microsoft's Office of Responsible AI, joins Sullivan to discuss how insights from genome editing could inform more nuanced and robust governance frameworks for emerging technologies like AI.

In the introductory episode of this new series, host Kathleen Sullivan and Senior Director Amanda Craig Deckard explore Microsoft’s efforts to draw on the experience of other domains to help advance the role of AI testing and evaluation as a governance tool.

Technologists Bill Gates and Sébastien Bubeck discuss the state of generative AI in medicine, how access to “medical intelligence” might help empower people across healthcare, and how AI’s accelerating improvements are likely to affect both delivery and discovery.

Ethan Mollick and Azeem Azhar, thought leaders at the forefront of AI’s influence on work, education, and society, discuss the impact of AI at the individual level and what that means for the healthcare workforce and the organizations and systems in medicine.

The emergence of foundation models has sparked interest in applications to single-cell biology, but when tested in zero-shot settings, they underperform compared to simpler methods. Alex Lu shares insights on why more research on AI models is needed in biological applications.

Show notes

In this episode of Abstracts, Microsoft senior researchers Megan Stanley and Wessel Bruinsma join host Amber Tingle to discuss their groundbreaking work on environmental forecasting. Their new Nature publication, "A Foundation Model for the Earth System," features Aurora, an AI model that redefines weather prediction and extends its capabilities to other environmental domains such as tropical cyclones and ocean wave forecasting.

Read the paper: A Foundation Model for the Earth System